Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease

Nicotinamide is a coenzyme involved in cellular oxidation-reduction reactions that can inhibit Class III histone deacetylases (HDACs) or sirtuins. HDAC inhibition can affect numerous therapeutic pathways, including tau phosphorylation. We tested the hypothesis that nicotinamide treatment could reduc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology 2025-01, Vol.104 (1), p.e210152
Hauptverfasser:	Grill, Joshua D, Tam, Steven, Thai, Gaby, Vides, Beatriz, Pierce, Aimee L, Green, Kim, Gillen, Daniel L, Teng, Edmond, Kremen, Sarah, Beigi, Maryam, Rissman, Robert A, Léger, Gabriel C, Balasubramanian, Archana, Revta, Carolyn, Morrison, Rosemary, Jennings, Robin, Pa, Judy, Zhang, Jing, Jin, Shelia, Messer, Karen, Feldman, Howard H
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Alzheimer Disease - cerebrospinal fluid Alzheimer Disease - drug therapy Amyloid beta-Peptides - cerebrospinal fluid Biomarkers - cerebrospinal fluid Double-Blind Method Female Humans Male Middle Aged Niacinamide - administration & dosage Niacinamide - adverse effects Niacinamide - therapeutic use Peptide Fragments Phosphorylation Proof of Concept Study tau Proteins - cerebrospinal fluid Treatment Outcome Vitamin B Complex - administration & dosage Vitamin B Complex - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!